Sugawara, Yuka
Kanda, Eiichiro
Ohsugi, Mitsuru
Ueki, Kohjiro
Kashihara, Naoki
Nangaku, Masaomi http://orcid.org/0000-0001-7401-2934
Funding for this research was provided by:
Japan Agency for Medical Research and Development (22mk0101172h0003)
The University of Tokyo
Article History
Received: 28 April 2023
Accepted: 11 September 2023
First Online: 9 October 2023
Declarations
:
: The contributing authors reported the following financial supports: YS and EK have nothing to declare regarding potential conflicts of interest relevant to this article. MO receives grants from Abbott Japan LLC, Astellas Pharma Inc., Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., MSD, Nippon Boehringer Ingelheim Co., Ltd, Novo Nordisk, and Sanofi, in addition to honorarium from Abbott Japan LLC, Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kowa, Mitsubishi Tanabe Pharma Corporation, MSD, Nippon Boehringer Ingelheim Co., Ltd, Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Pharma, Takeda Pharmaceutical Co., Ltd. and Teijin Pharma. KU receives grants from Abbott, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD, Novartis Pharma K.K., Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Pharma and Takeda Pharmaceutical Co., Ltd., in addition to honorarium from Astellas Pharma Inc., Boehringer Ingelheim GmbH, Eli Lilly Japan K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD, Novo Nordisk, Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Pharma and Takeda Pharmaceutical Co., Ltd.. NK has received lecture fees from Daiichi Sankyo Co., Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd., Nobelpharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Novartis Pharma K.K.; research funds from AstraZeneca K.K., Nobelpharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Bayer Yakuhin, Ltd.; and research grants from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., and Boehringer Ingelheim GmbH. MN has received lecture fees from Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Bayer Yakuhin, Ltd., and Japan Tobacco Inc.; fee for writing manuscript from Kyowa Kirin Co., Ltd.; research funds from EPS Corporation, Parexel International Inc., and Japan Tobacco Inc.; and research grants from Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd.
: All procedures were performed in accordance with the ethical standards of the Research Committee of the National Center for Global Health and Medicine (No: NCGM-G-002354-00;) and with those of the 1964 Helsinki Declaration and its later amendments.
: According to the Guidelines for Epidemiological Studies of the Ministry of Health, Labor, and Welfare of Japan, written informed consent was not required.